L Weiss, L E Fischer, V Heinemann, F Gieseler, T Hoehler, J Mayerle, D Quietzsch, A Reinacher-Schick, M Schenk, G Seipelt, J T Siveke, M Stahl, U Kaiser, D T Waldschmidt, K Dorman, D Zhang, C B Westphalen, S Boeck, M Haas
BACKGROUND: Over the past two decades, our group has conducted five multicenter trials focusing on first-line systemic therapy for patients with advanced pancreatic cancer. The current pooled analysis was designed to evaluate prognosis over time and the impact of clinical characteristics on survival. PATIENTS AND METHODS: Individual patient data were derived from five prospective, controlled, multicenter trials conducted by the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO): 'Gem/Cis', 'Ro96', 'RC57', 'ACCEPT' and 'RASH', which recruited patients between December 1997 and January 2017...
March 18, 2024: ESMO Open